On February 6, 2024 FibroBiologics (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, reported the issuance of three patents from the Japan Patent Office (JPO) to add to its portfolio (Press release, FibroBiologics, FEB 6, 2024, View Source [SID1234639894]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Issued Patents:

Japanese Patent 7333272, (Inventor: Pete O’Heeron) METHODS OF ENHANCING FIBROBLAST THERAPEUTIC ACTIVITY
Japanese Patent 7386162, (Inventor: Pete O’Heeron) AUGMENTATION OF FIBROBLASTS REGENERATIVE ACTIVITY
Japanese Patent 7387603, (Inventor: Pete O’Heeron) INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES THEREOF
"Incorporating this additional patent protection into our portfolio reinforces our leadership in this space," said Pete O’Heeron, Chief Executive Officer of FibroBiologics. "Japan holds significant importance in the field of cell therapy, and we remain committed to expanding and strengthening our protections within this pivotal market."